Clinical Trial Update: Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Acasunlimab plus Pembrolizumab vs. standard of care Docetaxel in PD-L1-positive non-small cell lung cancer is active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Acasunlimab (acasunlimab)
• DOCETAXEL (DOCETAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Genmab | Conditions: PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Phase 3 | Status: ACTIVE_NOT_RECRUITING